公开(公告)号：US20230016791A1

公开(公告)日：2023-01-19

申请号：US17821851

申请日：2022-08-24

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Marie Grandner ,  Daniel G.M. Shore ,  Marian C. Bryan

IPC: C07D487/04 ,  A61P11/06 ,  A61K9/00 ,  A61K9/19

Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20230167123A1

公开(公告)日：2023-06-01

申请号：US18063575

申请日：2022-12-08

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Jessica Grandner ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61P37/06

Abstract: Compounds of formula (I)




wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20220106322A1

公开(公告)日：2022-04-07

申请号：US17644742

申请日：2021-12-16

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Naomi S. Rajapaksa ,  Yun-Xing Cheng ,  Wei Li ,  Daniel G.M. Shore ,  F. Anthony Romero ,  Marian C. Bryan

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.